SCHEMBL7959611

SCHEMBL7959611

CCOC(=O)Cn1nc(Cc2cn(C)c3ccccc23)c2ccccc2c1=O

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 7/20 0.77
▸ CYP1A2 P05177 1/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ CYP2C9 P11712 1/20 0.68
▸ CYP2C19 P33261 1/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.68
▸ GAA P10253 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1847165 0.89 CMA1 (0.80) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL8739236 0.89 CMA1 (0.61) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7951727 0.87 CMA1 (1.00) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL18900854 0.83 CMA1 (0.76) CMA1RECQLALOX15TSHR
SCHEMBL7963507 0.82 CMA1 (0.73) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7959067 0.81 CMA1 (0.85) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL24076900 0.81 CYP1A2 (0.77) CYP1A2CYP3A4CYP2C9CYP2C19L3MBTL1
SCHEMBL7963672 0.80 CMA1 (0.67) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7963792 0.79 CYP1A2 (0.68) CMA1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7961041 0.78 CMA1 (0.80) CMA1CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323991-B1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-05-31 — — EP disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
WO-2010019417-A2 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129863-A1 CHYMASE INHIBITORS CMA1, CPA3, SERPINB1 CMA1 1/4885CYP1A2 2423/4885CYP3A4 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback